Table 1 Baseline characteristics and radiographic progression of the 101 patients included in the study by baseline TFNi treatment status.
N | TNFi treatment ≥ 4years n=46 (45.5%) | TNFi treatment < 4years n=55 (54.5%) | All n=101 | ||
|---|---|---|---|---|---|
Age, years | 101 | 46.0 (25.0, 75.0) | 47.0 (21.0, 75.0) | 46.0 (21.0, 75.0) | |
Female, sex % | 101 | 8 (17.4%) | 11 (20.0%) | 19 (18.8%) | |
Radiographic progression (mSASSS ≥ 2) | 101 | 15 (32.6%) | 15 (27.3%) | 30 (29.7%) | |
HLA-B27 positive, % | 99 | 43 (95.6%) | 43 (79.6%) | 86 (86.9%) | |
AS, % | 101 | 41 (89.1%) | 45 (81.8%) | 86 (85.1%) | |
BMI | 95 | 26.7 (19.8, 40.8) | 25.4 (19.4, 32.0) | 26.0 (19.4, 40.8) | |
Current smokers, % | 101 | 16 (34.8%) | 15 (27.3%) | 31 (30.7%) | |
Symptom duration, years | 97 | 19.0 (2.0, 52.0) | 11.0 (0.0, 50.0) | 15.0 (0.0, 52.0) | |
CRP (mg/L) | 94 | 2.9 (0.10, 26.0) | 4.3 (0.0, 88.7) | 3.4 (0.0, 88.70) | |
CRP < 5 | 94 | 27 (62.8%) | 26 (51.0%) | 53 (56.4%) | |
BASDAI (0-10) | 97 | 3.0 (0.2, 8.6) | 4.2 (0.40, 8.8) | 3.2 (0.20, 8.8) | |
BASDAI < 4 | 97 | 30 (66.7%) | 24 (46.2%) | 54 (55.7%) | |
ASDAS-CRP | 96 | 1.71 (0.2, 5.1) | 2.3 (0.3, 5.1) | 2.1 (0.2, 5.1) | |
Low disease (ASDAS < 2.1), % | 96 | 28 (63.6%) | 22 (42.3%) | 50 (52.1%) | |
Inactive disease (ASDAS <1.3), % | 96 | 10 (22.7%) | 13 (25.0%) | 23 (24.0%) | |
BASFI (0–10) | 98 | 3.6 (0.0, 9.1) | 4.2 (0.0, 9.3) | 3.9 (0.0, 9.3) | |
BASMI (0–10) | 82 | 2.9 (0.5, 7.3) | 3.0 (0.6, 6.4) | 2.9 (0.5, 7.3) | |
mSASSS (0–72) | 101 | 10.0 (0.0, 72.0) | 3.0 (0.0, 66.0) | 5.0 (0.0, 72.0) | |
Syndesmophytes present, % | 101 | 26 (56.5%) | 25 (45.5%) | 51 (50.5%) | |
On NSAID treatment, % | 99 | 23 (51.1%) | 34 (63.0%) | 57 (57.6%) | |
On TNFi treatment, % | 100 | 45 (100.0%) | 37 (67.3%) | 82 (82.0%) | |
Number of previous TNFi | 0 | 101 | 24 (52.2%) | 51 (92.7%) | 75 (74.3%) |
1 | 16 (34.8%) | 4 (7.3%) | 20 (19.8%) | ||
2 | 6 (13.0%) | 0 (0.0%) | 6 (5.9%) | ||
Months of TNFi treatment in treated patients | 82 | 84.0 (48.0, 132.0) | 19.0 (1.0, 43.0) | 51.0 (1.0, 132.0) | |
Uveitis | 101 | 10 (21.7%) | 12 (21.8%) | 22 (21.8%) | |
Psoriasis | 99 | 5 (11.1%) | 2 (3.7%) | 7 (7.1%) | |
IBD | 99 | 3 (6.7%) | 4 (7.4%) | 7 (7.1%) | |